Skip to content

Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions

Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06235580
Acronym
IFN
Enrollment
1000
Registered
2024-02-01
Start date
2015-12-28
Completion date
2035-12-27
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Diseases, Genetic Diseases, Immune Dysfunction, Neurological Disease

Brief summary

Over the past twenty years, Prof. Yanick Crow and his team have developed internationally recognized expertise in genetic pathologies affecting the immune and neurological systems. The pathologies studied have a particularly severe impact on patients' quality of life, with a high mortality rate and a significant risk of occurrence in affected families. These pathologies are rare, and very often under-diagnosed. To date, there is virtually no effective curative treatment. Prof. Crow's team operates at the frontier between clinical and research work, and from experience, the team knows that patients and families affected by these serious pathologies are often highly motivated to help research into the pathology that affects them. Initially, Prof. Crow's research focused primarily on the study of the genetic disease Aicardi-Goutières Syndrome (AGS). However, there is an undeniable clinical and pathological overlap between AGS and other forms of disease such as autoimmune systemic lupus erythematosus and many other genetic pathologies - e.g. familial lupus engelure, spondyloenchondromatosis and COPA syndrome. This is why research is being extended to all genetic diseases with immune and neurological dysfunctions.

Detailed description

The research methodology is classic with regard to many genetic clinical studies, and aims to: * clinically define the phenotypes of these diseases (in this case, genetic diseases with immune and neurological dysfunctions) * identify the gene(s) responsible for each disease * Understand how changes in these genes and protein functions cause these diseases. It is possible that this research will ultimately lead to the creation of diagnostic tests (e.g. molecular diagnostic screening tests) and treatments that would be clinically very useful for the patients participating in the project. These discoveries could also improve our knowledge of other more common pathologies, particularly those associated with autoimmunity (e.g. when the body increases an immune response against its own tissues). As a complement to this global research project, Prof. Crow's team intends to study cell populations from patients with no inflammatory pathology, in order to analyze their basal levels of immune and inflammatory mediator production, as well as to assess their capacity (kinetics and amplitude) to respond to stimuli.

Interventions

OTHERBiological Samples

For patients, different types of banked frozen or fresh biological samples will be used in this research: * Blood * Skin biopsy or other tissues (liver, muscle, brain, lung...) * Urine * Saliva * Cerebrospinal fluid * Occasionally: operative leftovers (e.g. muscle, brain, lung tissue) In control patients, we would like to collect operative remnants of cell types involved in the inflammatory and/or neurological diseases studied in the laboratory, if these patients require surgery as part of their management, and if any biological material remains after surgery. Under the same conditions, a sample of cerebrospinal fluid could be recovered. For unaffected relatives, a single blood sample of maximum 10 ml is taken at inclusion, and samples already taken during routine care are used.

Sponsors

Imagine Institute
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients : * Have / present a family history of genetic disease with immune and neurological dysfunction. * Have signed an informed consent form. * Unaffected related subjects : * Be related to a patient included in this research. * Have signed an informed consent form. * Control patients * Be free of any genetic disease with immune and neurological dysfunction. * Have undergone surgery as part of their management * Have signed an informed consent form. Non-inclusion criteria ✓ Be deprived of liberty

Design outcomes

Primary

MeasureTime frameDescription
Clinical features of human genetic diseases that affect the immune and neurological systems.through study completion, an average of 1 yearClinical features of human genetic diseases that affect the immune and neurological systems.
Natural history of human genetic diseases that affect the immune and neurological systems.through study completion, an average of 1 yearNatural history of human genetic diseases that affect the immune and neurological systems.
Molecular and cellular basis of human genetic diseases that affect the immune and neurological systems.through study completion, an average of 1 yearMolecular and cellular basis of human genetic diseases that affect the immune and neurological systems.

Countries

France

Contacts

Primary ContactYanick Crow, MD PhD
marie-louise.fremond@institutimagine.org
Backup ContactMarie-Louise Frémond, MD PhD
marie-louise.fremond@institutimagine.org

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026